more

Alexion Pharmaceuticals, Inc. (ALXN)

(Delayed Data from NSDQ)

$136.69 USD

+3.56 (2.67%)

Updated May 3, 2019 04:00 PM ET

After-Market: $136.70 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank	Definition	Annualized Return
1	Strong Buy	24.15%
2	Buy	17.88%
3	Hold	9.47%
4	Sell	5.14%
5	Strong Sell	2.57%
S&P	500	11.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score	A
Growth Score	A
Momentum Score	A
VGM Score	A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

Industry: NA

View All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Based in New Haven, CT, Alexion Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of life-transforming drugs, for the treatment of patients with ultra-rare disorders. The company’s complement franchise consists of key growth driver, Soliris, which is approved for the treatment of two severe and ultra-rare disorders resulting from chronic uncontrolled activation of the complement component of the immune system — paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS). Soliris is also approved for the treatment of generalized myasthenia gravis (gMG) in adults who are anti-acetylcholine receptor (AChR) antibody-positive. The FDA also approved its long-acting C5 complement inhibitor, Ultomiris, for the treatment of adult patients with PNH, to be administered every eight weeks. In October 2019, the FDA approved the use of Ultomiris as a treatment for adult and pediatric (one month of age or older) patients with aHUS to inhibit complement-mediated TMA.

Zacks.com featured highlights include: Insight, ConocoPhillips, Vale, Alexion and Archer Daniels

by Zacks Equity Research Published on August 02,2018

Zacks.com featured highlights include: Insight, ConocoPhillips, Vale, Alexion and Archer Daniels

5 Stocks Trading Near 52-Week High With More Upside in Store

by Zacks Equity Research Published on August 01,2018

Here are some stocks trading near their 52-week high levels with potential to scale higher.

Alexion's (ALXN) Earnings Beat Estimates in Q2, Guidance Up

by Zacks Equity Research Published on July 26,2018

ALexion (ALXN) beats both earnings and revenue estimates in the second quarter of 2018, and completes the acquisition of Wilson Therapeutics.

Alexion (ALXN) Tops Q2 Earnings and Revenues Beat Estimates

by Zacks Equity Research Published on July 26,2018

Alexion beat both earnings and sales estimates in the second quarter of 2018.

ALXNPositive Net Change

Alexion Pharmaceuticals (ALXN) Beats Q2 Earnings and Revenue Estimates

by Zacks Equity Research Published on July 26,2018

Alexion (ALXN) delivered earnings and revenue surprises of 22.49% and 6.55%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?

ALXNPositive Net Change

Drug Stocks to Report Earnings on Jul 26: AMGN, ALXN & More

by Zacks Equity Research Published on July 25,2018

Let's see how these five pharma/biotech stocks are poised ahead of their scheduled results on Jul 26.

Is a Beat in Store for Alexion (ALXN) This Earnings Season?

by Zacks Equity Research Published on July 23,2018

Alexion is likely to provide details about the pipeline portfolio when it reports its second-quarter 2018 results on Jul 26.

Amgen (AMGN) to Report Q2 Earnings: Will it Beat Again?

by Zacks Equity Research Published on July 23,2018

While Amgen's (AMGN) growth drugs like Prolia & Xgeva might do well, biosimilar competition and slowdown in sales of mature products can put pressure on sales growth.

ALXN or RGNX: Which Is the Better Value Stock Right Now?

by Zacks Equity Research Published on July 19,2018

ALXN vs. RGNX: Which Stock Is the Better Value Option?

by Zacks Equity Research Published on July 19,2018

ALXN vs. RGNX: Which Stock Is the Better Value Option?

Karyopharm Initiates NDA Submission Process for Selinexor

by Zacks Equity Research Published on July 19,2018

Karyopharm Therapeutics (KPTI) initiates rolling submission of a New Drug Application to the FDA with a request for accelerated approval for selinexor.

J&J (JNJ) Faces $4.69 Billion Verdict in Talc Case (Revised)

by Zacks Equity Research Published on July 18,2018

A Missouri jury asked Johnson & Johnson (JNJ) to pay $4.69 billion in damages to 22 women and their families, who alleged that the company's baby powder contained asbestos that caused them to develop ovarian cancer.